Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results GlobeNewswire August 12, 2025 • New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent […]

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates GlobeNewswire August 12, 2025 Muzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial design elements. Company

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire August 12, 2025 – Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in Q4 2025 – Phase 2 ASPEN-Breast evorpacept

AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire August 12, 2025 – Multiple near-term potential milestones, including anticipated completion of primary structure analysis and select functional analyses in 3Q'25 – – Type 2a meeting with the FDA anticipated in 4Q'25- – Cash runway expected to support operations through FDA meeting

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights GlobeNewswire August 12, 2025 Received FDA feedback on Pre-IND Briefing Document reinforcing Company's intention to advance investigational new drug (IND) submission for CUE-401 to address unmet need in the treatment of autoimmune disease. Announced strategic research collaboration and license agreement with Boehringer Ingelheim

Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results GlobeNewswire August 12, 2025 Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half of 2028 Expanded ongoing collaboration with Almirall, with election of a

Inspirato Reports Q2 Financial and Operating Results Strong operational execution continues ahead of strategic combination with Buyerlink to form One Planet Platforms, a leading platform for building and operating online marketplaces, enhancing Inspirato's luxury travel offerings and global reach GlobeNewswire August 12, 2025 DENVER, Aug. 12, 2025 (GLOBE NEWSWIRE) — Inspirato Incorporated (“Inspirato” or the

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 GlobeNewswire August 12, 2025 Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphoma Initiated the PiNACLE pivotal trial of LYL314 in patients with large

(NASDAQ:KYTX), Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) andBLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients with enrollment to initiate by year-end 2025; interim Phase 2 data expected in Q4 2025 Strong cash position to support upcoming

Q2 U.S. Galleri Revenue Grew 21% Year-Over-Year to $34.2 Million Q2 Galleri Tests Sold Grew 29% Year-Over-Year to More Than 45,000 Detailed Results From First 25,000 Enrolled in PATHFINDER 2 to be Submitted for Presentation at ESMO 2025 in October GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when